ApoM-Fc fusion proteins for treating lung diseases

Patent metadata

Field	Value
Publication number	US-12415847-B2
Application number	US-201917284299-A
Country	US
Kind code	B2
Filing date	Oct 11, 2019
Priority date	Oct 12, 2018
Publication date	Sep 16, 2025
Grant date	Sep 16, 2025

Abstract

Provided herein are methods of treating lung disease using fusion proteins comprising ApoM (e.g., human or murine ApoM) fused to a constant region (Fc) of a immunoglobulin G (IgG, e.g., human IgG or murine IgG).

First claim

What is claimed is:

1. A method of decreasing the severity of one or more symptoms associated with bronchopulmonary dysplasia (BPD) or congenital diaphragmatic hernia (CDH), the method comprising administering to a subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (lgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5 or SEQ ID NO: 6, wherein the Fc comprises an amino acid sequence that is 96% identical to SEQ NO 7 or SEQ ID NO: 8.

2. The method of claim 1 , wherein the fusion protein further comprises a signal peptide fused to the ApoM.

3. The method of claim 1 , wherein the ApoM is fused at the N-terminus of the Fc.

4. The method of claim 1 , wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5.

5. The method of claim 1 , wherein the fusion protein comprises an amino acid sequence that is at least 96% identical to any one of SEQ ID NOs: 1-4 and 9.

6. The method of claim 1 , wherein the fusion protein is cross-linked, cyclized, conjugated, acylated, carboxylated, lipidated, acetylated, thioglycolic acid amidated, alkylated, methylated, polyglycylated, glycosylated, polysialylated, phosphorylated, adenylylated, PEGylated, or combinations thereof.

7. The method of claim 1 , wherein the fusion protein activates a SIP receptor.

8. The method of claim 1 , wherein the fusion protein is administered intravenously, intranasally, intratracheally, intramuscularly, or by inhalation.

9. The method of claim 1 , wherein the subject is human, and the ApoM comprises the amino acid sequence of SEQ ID NO:5 and the Fc comprises the amino acid sequence of SEQ ID NO 7.

10. The method of claim 9 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

11. A method of decreasing the severity of one or more symptoms associated with Bronchopulmonary Dysplasia (BPD), the method comprising administering to a human subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (IgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5, and wherein the Fc comprises the amino acid sequence of SEQ ID NO 7.

12. The method of claim 11 , wherein the human subject was born prematurely or was exposed to hyperoxia as a newborn.

13. The method of claim 11 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

14. The method of claim 11 , wherein the fusion protein restores lung architecture.

15. A method of decreasing the severity of one or more symptoms associated with Congenital Diaphragmatic Hernia (CDH), the method comprising administering to a human subject in need thereof a therapeutically effective amount of a fusion protein comprising an apolipoprotein M (ApoM) fused to a constant region (Fc) of an immunoglobulin G (lgG), wherein the ApoM comprises the amino acid sequence of SEQ ID NO: 5, and wherein the Fc comprises the amino acid sequence of SEQ ID NO 7.

16. The method of claim 15 , wherein the fusion protein is administered to the human subject in utero, within one hour to one year after birth, or when the human subject is an adult.

17. The method of claim 15 , wherein the fusion protein increases lung regeneration and growth, and/or restores lung development.

18. The method of claim 1 , wherein the one or more symptoms associated with BPD or CDH are selected from the group consisting of: bluish skin, chronic cough, rapid breathing, and shortness of breath.

19. The method of claim 5 , wherein the fusion protein comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 1.

20. The method of claim 19 , wherein the fusion protein comprises the amino acid sequence of SEQ ID NO: 1.

21. The method of claim 5 , wherein the fusion protein comprises the amino acid sequence of any one of SEQ ID NOs: 1-4 and 9.

22. The method of claim 4 , wherein the Fc comprises an amino acid sequence that is at least 99% identical to the amino acid sequence of SEQ ID NO: 7.

Assignees

• Childrens Medical Center

Inventors

• Hla Timothy T
• Swendeman Steven L
• Puder Mark
• Smith Lois

Classifications

• C07K2319/30

  Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto · CPC title

• A61K38/00

  Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00) · CPC title

• A61P11/00

  Drugs for disorders of the respiratory system · CPC title

• A61K38/1709

  from mammals · CPC title

• A61K47/68

  the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment · CPC title